PHARMAC is seeking feedback on a provisional agreement with Apotex NZ Limited, for diltiazem hydrochloride (Apo-Diltiazem CD) long-acting capsules 120 mg, 180 mg, and 240 mg from 1 July 2015.

In summary, this proposal would result in long-acting diltiazem hydrochloride remaining listed as the current price and subsidy with subsidy and delisting protection until 30 June 2018.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-04-07-diltiazem-hydrochloride/